View Post

Roche drug is third to win biomarker-driven cancer approval from FDA

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: Another drug designed to treat cancer patients based on a genetic driver rather than where tumors occur in the body has received approval from the Food and Drug Administration. The FDA on Thursday granted Swiss drugmaker Roche’s Rozlytrek (entrectinib) approval for ROS1-positive non-small cell lung cancer and accelerated approval for solid tumors with NTRK gene …